

Multiple Sclerosis Referral Form

Phone (888) 370.1724 Fax: (877) 645.7514 10004 S. 152nd St, Suite A, Omaha NE 68138

Patient Info	rmation	First Name					Homo P	hono			l v	Nork/Mob	ilo Phono			
Last Name	ist value			ic				Home Phone				Work/Mobile Phone				
Home Address							City				İ	State	ZI	Р		
Shipping Address (if di	fferent from above)						City				5	State	ZIP			
Social Security Numbe	Gender (M/	/F) Weight/Recor	ded Date	Date of Bir	rth	Allergies										
Emergency Contact	Pho	ne			Primar	y Caregiver			Pł	none						
Healthcare	Provider Informa	tion:														
Practice/Facility Name					Physic	ian Name				Phone/	Fax					
Address							City				(State	ZI	P		
Physician NPI #	ysician NPI # Nurse/Key Conta			act			Phone or Pager Number				Email					
Delivery Inf	ormation:															
Insurance a	nd Clinical Inform	nation: PL	EASE FA	X A CO	PY O	F INSU	RANCE	CARD (FRON	T AND	BAC	()				
Is patient curren Number of Relay Will patient disc Discontinuation	viously been treated for the titly on therapy? YES poses in past year: ontinue therapy prior to Date:	this condition? NO starting new t	herapy? □	YES 🗆		Last MR Injection Novantro What is Copy of I	I Date: _ Training one: Is p ifetime (ast CBC	Needed I g Needed I atient's LV cumulativ with differne:	oy Amb EF <50 e) Nova rential:	ny MRI er Phar 0%? 🗖 antrone	Change macy? YES [dose (r	s? UY YES NO ng/m2)	ES NO NO?			
Medication	Dose/Strength		Sig									0	ty.	Refills		
☐ Avonex®	□ 30mcg Prefilled Syri		0.0													
	□ 30mcg Pen #4	inge #4	■ Inject 3	Omcg IM	once	weekly							week sup	ply		
□ Betaseron®	,		Dose Ti	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir	nject (nject (nject (0.0625mg 0.125mg/ 0.1875mg 0.25mg/1	0.50ml g/0.75m ml SC Q	SC QOD I SC QOD OD				4.				
□ Betaseron®	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrin	nge	Dose Ti Wee Wee Wee Wee Mainter Other:	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir nance Do:	nject (nject (nject (0.0625mg 0.125mg/ 0.1875mg 0.25mg/1	0.50ml g/0.75m ml SC Q	SC QOD I SC QOD OD				4 4	week sup	ply		
□ Copaxone®	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrin □ 40mg Prefilled Syrin	nge nge	Dose Ti Wee Wee Wee Wee Mainter Other: 20mg S	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir nance Dos	nject (nject (nject (nject C se: O.:	0.0625mg 0.125mg/ 0.1875mg 0.25mg/1 25mg/1m	0.50ml g/0.75m ml SC Q0	SC QOD I SC QOD OD D				4 4	week sup	ply		
	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrin	nge	Dose Ti Were Were Were Were Mainter Other: 20mg S 40mg S Were Were Were Were	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir nance Do: GC QD SC QD	nject (nject	0.0625mg 0.125mg/ 0.1875mg 0.25mg/1 25mg/1m 25mg/1m 0.0625mg 0.125mg/ 0.125mg/	0.50ml \$\footnote{0.75mm} of \$Q\$ of	SC QOD I SC QOD D D D I SC QOD SC QOD I SC QOD I SC QOD I SC QOD				4 4 4 4	week sup week sup week sup week sup	ply ply ply		
□ Copaxone® □ Extavia®	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrin □ 40mg Prefilled Syrin □ 0.3mg vial	nge nge	Dose Ti	itration: eks 1-2: II eks 5-6: II eks 7+: Ir nance Do: GC QD nance Do: itration: eks 1-2: II eks 3-4: II eks 7+: Ir	nject (nject	0.0625mg 0.125mg/ 0.1875mg 0.25mg/1 25mg/1m 25mg/1m 0.0625mg 0.125mg/ 0.125mg/	0.50ml \$\footnote{0.75mm} of \$Q\$ of	SC QOD I SC QOD D D D I SC QOD SC QOD I SC QOD I SC QOD I SC QOD				4 4 4 4	week sup week sup week sup week sup	ply ply ply		
□ Copaxone®	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrin □ 40mg Prefilled Syrin	nge nge ncg/22mcg) inge inge	Dose Ti Were Were Were Were Mainter Comp S Mainter Dose Ti Were Were Were Were Were Unject 8 22mcg S	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir nance Do: itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir PO QD 3.8mcg SO SC three SC three nance: Inj	nject (nject	0.0625mg/ 0.125mg/1 0.1875mg/1 0.25mg/1m 25mg/1m 0.0625mg/ 0.1875mg/ 0.1875mg/ 0.25mg/1	0.50ml g/0.75mml SC Q0 g/0.25mml SC Q0 g/0.25mml SC Q0 week for eeks 3-4 eeks 5+ml) SC t	SC QOD I SC QOD DD D I SC QOD SC QOD I SC QOD OD weeks 1-2 I, and (48 hours hree times	apart) s a wee	k (48 h		4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 ·	week sup week sup week sup week sup	ply ply ply		
□ Copaxone® □ Extavia®	□ 30mcg Pen #4 □ 0.3mg vial □ 20mg Prefilled Syrir □ 40mg Prefilled Syrir □ 0.3mg vial □ 0.5mg capsule □ Titration Pack (8.8m □ 22mcg Prefilled Syri	nge nge ncg/22mcg) inge inge	Dose Ti	itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir nance Do: itration: eks 1-2: II eks 3-4: II eks 5-6: II eks 7+: Ir PO QD 3.8mcg SO SC three SC three nance: Inj	nject (nject	0.0625mg/ 0.125mg/1 0.1875mg/1 0.25mg/1m 25mg/1m 0.0625mg/ 0.1875mg/ 0.1875mg/ 0.25mg/1	0.50ml g/0.75mml SC Q0 g/0.25mml SC Q0 g/0.25mml SC Q0 week for eeks 3-4 eeks 5+ml) SC t	SC QOD I SC QOD DD D I SC QOD SC QOD I SC QOD OD weeks 1-2 I, and (48 hours hree times	apart) s a wee	k (48 h		4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 · 4 ·	week sup week sup week sup week sup	ply ply ply		

Physician Signature:	DAW (Dispense as Written) Dat	e/	/	/